Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast

ACADIA reported Q1 2026 revenue of $268 million, up 11% year over year, but missed EPS at $0.02 versus $0.05 expected and revenue versus $280.92 million consensus. DAYBUE sales rose 20% to $101 million, NUPLAZID sales increased 6% to $167 million, and the company reaffirmed full-year 2026 revenue guidance of $1.22 billion-$1.28 billion. Shares still rose 1.25% aftermarket, supported by a strong cash balance of $851 million and optimism around DAYBUE STIX and the remlifanserin pipeline.

Analysis

ACAD’s setup is more interesting than the headline miss suggests: the company is effectively asking the market to underwrite a near-term P&L dip in exchange for a higher-quality revenue mix and a pipeline binary later this year. The operating leverage story is delayed, not broken — the key incremental is that commercial spending is now front-loaded while the next 2-3 quarters should show the payback from a larger field force and the broader rollout of the new formulation. That creates a classic inflection trade: downside is mostly finite if refill normalization holds, while upside expands materially if launch conversion accelerates in the community.

The second-order winner is not just ACAD, but the ecosystem around specialty neurology launches: specialty pharmacy, patient-support infrastructure, and any channel partner exposed to rare-disease adherence improvement. DAYBUE STIX matters because it can shift the economics from pure new-start acquisition to restart capture, which is a higher-margin growth vector and should improve lifetime value per patient. If that restart cohort proves durable, the market is likely underestimating the slope of growth into 2H26 and the probability that the “aspirational” medium-term revenue target gets pulled forward.

The biggest hidden risk is not the quarter itself; it is pipeline timing compression and expectation risk. The Alzheimer’s readout is the real catalyst, but the market will likely treat it as a yes/no event on both technical and regulatory de-risking, making any ambiguity around effect size or safety disproportionately painful. A negative or merely mediocre readout would force investors to re-rate ACAD back toward a mature commercial pharmaco, where the current multiple is too rich for a standalone growth story. Conversely, positive data plus no black-box signal would re-open a much higher terminal value scenario.

Consensus is probably too focused on the earnings miss and not enough on the sequencing: commercial re-acceleration first, pipeline optionality second. That is why the stock can hold up despite the miss — investors are implicitly paying for the right to own the binary ahead of the readout, while ignoring that the commercial story can still work even if the P&L stays noisy. The market is underpricing the possibility that a single positive data event in the next 4-5 months turns ACAD from a one-brand story into a multi-product neurology platform.

Key Decisions for Investors

• Go long ACAD into the August-October remlifanserin readout via a staged entry over the next 2-3 weeks; target 15-25% upside if data are statistically clean and safety is clean, with stop-loss discipline on any post-data gap if effect size misses the powered range.
• Buy ACAD call spreads on 3-6 month expiry to express the asymmetric catalyst without paying full event premium; best risk/reward if implied volatility stays elevated but not extreme.
• Pair trade: long ACAD / short a mature biotech cash-flow name over the next 1-2 quarters to isolate catalyst-driven rerating versus slower-growth defensives.
• If you already own ACAD, hedge the event with a small short-dated put spread rather than outright trimming; the commercial floor is improving, but the pipeline binary can dominate tape reaction.
• For event-driven accounts, consider taking profits into any pre-readout run-up above the recent trading range, then re-enter on post-data confirmation or a selloff tied only to short-term earnings noise.